TABLE 2

Effect of PPARγ antagonism

Preincubation (48 h)Insulin in medium (ng/ml)
Insulin content (μg/ml)
Ratio
3.37.51120P3.37.51120P3.37.51120P
[11 mmol/l]G13 ± 165 ± 497 ± 1284 ± 62.8 ± 0.22.4 ± 0.22.5 ± 0.22.7 ± 0.30.5 ± 0.12.7 ± 0.33.8 ± 0.63.1 ± 0.2
[11 mmol/l]G + [0.2 mmol/l]SR12 ± 177 ± 7109 ± 2084 ± 15NS2.8 ± 0.32.7 ± 0.22.7 ± 0.32.5 ± 0.3NS0.4 ± 0.12.7 ± 0.13.7 ± 0.33.3 ± 0.4NS
[11 mmol/l]G + [0.4 mmol/l]SR15 ± 159 ± 770 ± 851 ± 6*2.6 ± 0.22.3 ± 0.22.5 ± 0.12.7 ± 0.2NS0.6 ± 0.12.6 ± 0.32.7 ± 0.21.8 ± 0.2
  • * P < 0.002 and

  • P < 0.01 vs. [11 mmol/l]G; n = 21, 24, and 36 for the three rows. [11 mmol/l]G, 11 mmol/l glucose; [0.2 mmol/l]SR, 0.2 mmol/l SR202 (PPAR-γ antagonist; [0.4 mmol/l]SR, 0.4 mmol/l SR202 (PPAR-γ antagonist).